Figure 4 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

Figure 4 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

<p>Kaplan–Meier curve for PFS in patients with conventional CS treated with ivosidenib. CI, confidence interval; mPFS, median PFS.</p>

Saved in:
Bibliographic Details
Main Author: William D. Tap (15017801) (author)
Other Authors: Gregory M. Cote (15036672) (author), Howard Burris (21468938) (author), Lia Gore (15117508) (author), Anthony Elias (14946442) (author), Murali Beeram (21468941) (author), Anthony P. Conley (15294458) (author), Diego A. Gianolio (21468944) (author), Zhe Qu (21468947) (author), Susan Pandya (21468950) (author), Jonathan C. Trent (15044234) (author)
Published: 2025
Subjects:
Cancer
Therapeutic Research and Development
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Sarcomas
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<p>Kaplan–Meier curve for PFS in patients with conventional CS treated with ivosidenib. CI, confidence interval; mPFS, median PFS.</p>

Similar Items